# Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

> **NCT06890923** · PHASE2 · RECRUITING · sponsor: **Tiziana Life Sciences LTD** · enrollment: 55 (estimated)

## Conditions studied

- Non-Active Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Foralumab TZLS-401 100 µg

## Key facts

- **NCT ID:** NCT06890923
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-04
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06890923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06890923, "Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06890923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*